Lymphadenopathy after BCG vaccination in a child with chronic granulomatous disease by Vieira, AP et al.
 Pediatric Dermatology
 
Vol. 21 No. 6 646–651, 2004
 
646
 
Address correspondence to Ana Paula Vieira, M.D., Serviço de
Dermatologia, Hospital de S. Marcos, Apartado 2242, 4701-965
Braga, Portugal, or e-mail: dermato@hsmbraga.min-saude.pt.
 
Blackwell Publishing, Ltd.Lymphadenopathy After BCG Vaccination in a 
Child with Chronic Granulomatous Disease
 
Ana Paula Vieira, M.D.,* Júlia Vasconcelos, M.D.,† José Carlos Fernandes, M.D.,* Henedina 
Antunes, M.D.,‡ A. Sousa Basto, M.D.,* Cristiana Macedo, M.D.,* Afsana Zaman, M.D.,* 
Eugénia Santos, M.D.,† J. Castro Melo, M.D.,† and Dirk Roos, M.D.§ 
 
 Departments of 
 
*
 
Dermatology and 
 
‡
 
Pediatrics, S. Marcos Hospital, Braga, Portugal; 
 
†
 
Department of Immunology, S. 
António Hospital, Porto, Portugal; and 
 
§
 
Sanquin Research, Landsteiner Laboratory, Academic Medical Center, 
University of Amsterdam, Amsterdam, The Netherlands 
 
Abstract:
 
We report a 15-month-old boy who developed an ulcer in the
left axillary fold following bacillus Calmette-Guérin vaccination. Subsequent
immunologic and genetic studies led to the diagnosis of chronic granulo-
matous disease. His mother had “lupus-like” lesions, described in some
carriers of this disease, that were thus related to her son’s diagnosis.
Although in healthy subjects this vaccination is usually harmless, in
instances of impaired immunity it may cause adverse reactions. When a
vaccine-related complication occurs, an underlying immunodeficiency
 
should be sought.
 
Bacillus Calmette-Guérin (BCG) vaccination is usually
harmless, however, it can cause specific complications
resulting from the interaction of the host with the live
bacillus. The frequency of these complications is not
well known, but the incidence is certainly very low
if we consider the large number of vaccines that are
administered yearly (1). Benign regional adenitis is the
most common complication, especially in the younger
age group. Some patients may develop scrofuloderma,
which can persist for 6–12 months (1,2). In cases of
impaired immunity, vaccination can cause disseminated
BCG infection, which may be lethal (3,4).
Chronic granulomatous disease (CGD) is a rare pri-
mary immunodeficiency in which a deficiency of the
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase enzyme complex, which generates microbicidal
reactive oxygen species in phagocytes, renders these
cells inefficient at killing the ingested microorganisms.
As a consequence, recurrent infections with poor response
to therapy are common, with abscess formation in the
skin, soft tissue, lungs, and liver and suppurative
lymphadenopathy in the cervical lymph nodes (5,6).
Excessive formation of granulomas in all tissues is also
common (7).
We report a 15-month-old boy who developed axillary
lymphadenopathy after BCG vaccination. After subse-
quent immunologic function and genetic investigations,
a diagnosis of CGD was made. The child’s mother had
“lupus-like” lesions on her face and hands, as previously
described in carriers of CGD.
 
CASE REPORT
 
An apparently healthy 15-month-old boy with a good
nutritional status and growth in the 25th percentile
presented to the dermatology service in May 2000 with
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a deep ulcer in the left axillary fold (Figs. 1 and 2) that
had developed over the previous year. This lesion had
evolved from lymphadenopathy that had appeared 3
months after BCG vaccination. The child also had a soft,
erythematous, nodular lesion on the left wrist of 3-
months duration (Fig. 2). Except for these lesions, the
physical examination was normal, with no evidence of
other lymphadenopathy or hepatosplenomegaly.
Previously the child had been treated for 7 months
with isoniazid, which did not improve his ulcer or pre-
vent the appearance of an additional lesion on the wrist.
His past medical history included separation of the
umbilical cord at 15 days after birth, several upper respi-
ratory infections, and a urinary tract infection that
subsided quickly with antibiotics. He had a routine
vaccination program (diphtheria, pertussis, and tetanus
[DPT] vaccine and anti-
 
Haemophilus
 
 vaccine at 2, 4,
and 6 months of age, measles-mumps-Rubella [MMR]
at 15 months, and a booster of 
 
Haemophilus
 
 vaccine at
18 months) without any complications.
His family history was of significance in that the child’s
mother, age 24 years, has had relapsing erythematous,
maculopapular lesions on her hands since childhood.
More recently, similar lesions also appeared on her face.
She had been followed at the dermatology department
for suspicion of lupus erythematosus, although this
diagnosis was never confirmed, despite several tests for
autoantibodies and studies of skin biopsy specimens.
Blood studies of the child found a hemoglobin of 9.3
g/dl, hematocrit 28.9%, anisocytosis, anisochromasia,
and poikilocytosis. Results within the normal range were
obtained for the number of leukocytes (and for neutro-
phils), for tests of hepatic and renal function, electro-
phoresis of proteins, and 
 
α
 
1
 
-antitrypsin. Erythrocyte
sedimentation rate and C-reactive protein were elevated
(38 mm and 26.2 m/L, respectively). Serum levels of
IgA and IgG were elevated (156 mg/dl and 1710 mg/dl,
respectively), and antinuclear antibodies were negative.
The cutaneous Mantoux test was negative (5 mm). A
chest radiograph and renal and pelvic ultrasound scans
did not detect any anomaly. Histopathology of the axil-
lary and wrist lesions showed a chronic granulomatous
process with giant multinucleated cells. No alcohol-acid
resistant bacilli were detected in the biopsy specimens
nor in the exudate of the lesion.
In view of these results, the decision was made to add
rifampicin to the treatment with isoniazid. After 3
months of this double antituberculosis therapy, there was
complete regression of the wrist lesion and marked
improvement of the axillary ulcer, which was reduced to
a small exudative lesion. Medication was discontinued
due to diarrhea that was difficult to control. Two months
later a new nodular lesion, similar to the one on the wrist,
appeared close to the left labial commissure (Fig. 3).
A detailed immunologic study was performed to con-
firm the suspicion of a primary immunodeficiency.
Immunophenotyping of the B, T, and natural killer (NK)
cells did not reveal any significant abnormalities other
than evidence of strong T-cell activation (increased
expression of HLA-DR and CD45RO), which was
ascribed to recent infections. Expression of adhesion
molecules (CD18/CD11) and myeloperoxidase on the
leukocytes were normal. Functional studies of phago-
cytic cells showed a profound reduction in the oxidative
burst of the granulocytes and monocytes (Table 1) when
analyzed by flow cytometry as the fluorescence emitted
by oxidation of dihydrorhodamine (Bursttest, Orpegen
Pharma, Heidelberg, Germany) upon stimulation of
the cells with 
 
Escherichia coli
 
 or phorbol myristate ace-
tate (PMA). These results are fully compatible with
Figure 1. Ulcer in the left axillary fold.
Figure 2. Ulcer in the left axillary fold and nodular lesion on
the wrist.
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abnormalities usually seen in CGD. The expression of
the NADPH oxidase protein gp91
 
phox
 
 by the phagocytic
cells studied by flow cytometry with mAb 7D5 was
undetectable, indicating that the patient probably had an
X-linked form of CGD.
The study of the oxidative burst of the phagocytic
cells of the patient’s mother (after stimulation with 
 
E.
coli
 
 or PMA) clearly discriminated two granulocyte popu-
lations, with 60% of the cells showing a markedly
reduced oxidative burst, while the remaining 40% had
normal fluorescence. In concordance with these results,
the expression of gp91
 
phox
 
 was undetectable in 57% of
the mother’s granulocytes, but showed normal levels
in the remaining cells. These results confirm that the
mother is a carrier of X-linked CGD and hence indicate
that the patient’s defect is inherited.
The molecular characterization of the genetic defect,
by mutation analysis of DNA, revealed a mutation in the
X-CGD gene 
 
CYBB
 
. This mutation consists of an
inserted G after the G-6 and leads to a frame shift and
to a stop codon in codon 8. The same mutation was
detected in heterozygous form in the mother.
After a 1-month suspension, antituberculosis therapy
with isoniazid and rifampicin was resumed for 12 months,
with good results. At this time, a prophylactic treat-
ment with trimethoprim-sulfamethoxazole (4 mg/kg/
day, twice a day) and itraconazole (5 mg/kg/day,
twice a day) was also started and has been maintained
up to the present time with no secondary effects. Pres-
ently the child remains without infection or any other
complication.
 
DISCUSSION
 
Vaccination with the attenuated strain of 
 
Mycobacterium
bovis
 
 bacilli Calmette-Guérin is well tolerated and
adverse reactions are rare, although it is the one of the
most widely used vaccines in the world. When reactions
do occur, specific complications of the vaccination
usually consist of benign lymphoglandular and skin
reactions that mimic cutaneous responses to “natural”
mycobacterial infection (1,2). Occasionally, in children
with impaired immunity, disseminated BCG infection
may occur, and sometimes is lethal. Most of these
children have combined immunodeficiency and some
have CGD (3,4).
Initially our patient’s suppurative lymphadenitis was
interpreted as a specific complication of the BCG
vaccine and, as recommended by several protocols,
treatment with isoniazid was started (8). Failure of this
treatment regime, denoted by the associated emergence
of cutaneous granulomas at other sites, led us to investi-
gate a possible immunodeficiency, and as a result, the
diagnosis of CGD was made.
Chronic granulomatous disease was definitively recog-
nized as a disease of the phagocytes in the 1960s,
when it was demonstrated that neutrophils of these
patients have a specific deficiency in the intracellular
killing of bacteria. This deficiency was traced to a defect
in the oxidative metabolism of phagocytes, manifested
as an absence of the “respiratory burst” that occurs dur-
ing phagocytosis (9,10). The oxidative activity of phago-
cytes is catalyzed by NADPH oxidase, which performs
the monovalent reduction of molecular oxygen (O
 
2
 
) to
superoxide anions (O
 
2
–
 
). This free radical is in turn con-
verted (spontaneously or catalyzed by superoxide dis-
mutase) to hydrogen peroxide (H
 
2
 
O
 
2
 
), which can be
used by the neutrophil enzyme myeloperoxidase (MPO)
for conversion into microbicidal intermediates that cause
the destruction of the phagocytized microorganisms
(6,9). NADPH oxidase is a multicomponent enzyme,
with membrane-bound components, the 91 kDa glyco-
protein gp91
 
phox
 
, and the 22 kDa protein p22
 
phox
 
, which
functionally interact with cytoplasmic components, the
47 kDa protein p47
 
phox
 
, and the 67 kDa protein p67
 
phox
 
(9,11). Mutations in the genes of any of these four
proteins can cause CGD. Since 
 
CYBB
 
, the gene that
Figure 3. Nodular lesion on the face.
TABLE 1. Results of the Oxidative Burst of the Granulocytes
and Monocytes of the Patient Activated with PMA or E. coli
 
Activation
Percent positive cells 
(patient /50 controls)
Median fluorescence intensity 
of the positive cells (channel) 
(patient /50 controls)
PMA Granulocytes: 12/96–100 Granulocytes: 0.930/19.6–81.15
E. coli Granulocytes: 79/94–100 Granulocytes: 1.330/6.59–31.53
Monocytes: 22/34–96 Monocytes: 0.800/3.07–11.09
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encodes gp91
 
phox
 
, is located on the X chromosome,
mutations in 
 
CYBB
 
 cause the X-linked form of CGD.
Chronic granulomatous disease is a rare disease, with
an estimated incidence of 1 in 250,000, and has a
marked male predominance due to the most common
mode of genetic inheritance (11). Manifestations of the
disease are usually seen before the age of 2 years as
recurrent infections on the epithelial surfaces that are in
direct contact with the environment, such as the skin,
lungs, and gastrointestinal tract (12). The most common
presenting feature is lymphadenitis, particularly of the
cervical nodes, followed by cutaneous abscesses, pneu-
monia, hepatomegaly, and diarrhea. Hepatic abscess,
osteomyelitis, and sepsis may also occur (12). In addi-
tion, there is an excessive formation of granulomas in all
tissues (7). The main cutaneous manifestations include
abscesses, pyoderma with local lymphadenopathy, and
dermatitis in periorificial areas (5,6). In the literature
there are descriptions of oral and perioral ulcerations,
chronic gingivitis, scalp folliculitis, chronic suppurative
paronychia, and poor healing of surgical wounds (6).
The microorganisms responsible for most of the
infections in CGD are catalase-positive bacteria such as
 
Staphylococcus aureus
 
 and gram-negative Enterobacteri-
aceae, including 
 
Salmonella
 
, 
 
Klebsiella
 
, 
 
Aerobacter
 
,
 
Serratia
 
, and some species of 
 
Pseudomonas
 
, particularly
 
Burkholderia cepacia
 
. The fungus most commonly
implicated in CGD is 
 
Aspergillus
 
, predominantly 
 
A.
fumigatus
 
 (6,7). Catalase-negative bacteria like 
 
Strepto-
coccus
 
 rarely cause problems, since the small amounts
of hydrogen peroxide that these bacteria produce are not
degraded by catalase and are therefore available within
the phagocytic vacuoles for the production of micro-
bicidal intermediates (9). Less common than infections are
cutaneous granulomas, which are frequently nodular and
necrotic; these can appear at the inoculation site
(6,9,11). Mycobacterial disease is uncommon in patients
with CGD, but draining skin lesions and lymphadeno-
pathy can occur at the site of BCG inoculation. Focal or
miliary pulmonary disease may arise as a result of infec-
tion with nontuberculous mycobacteria, and may be
followed by pulmonary fibrosis (7).
Children with CGD usually have short stature and
low weight. The end of the first decade of life represents
a turning point for these patients, as thereafter the infec-
tions are usually less frequent and less severe (11,12). In
laboratory tests, one frequently sees hypergammaglobu-
linemia, anemia, and an increased erythrocyte sedimen-
tation rate, probably as a reflection of an ongoing
subclinical inflammation status (11,12).
The diagnosis of CGD is based on laboratory demon-
stration of the inability of phagocytes from affected indi-
viduals to produce a normal respiratory burst. For that
purpose, the nitroblue tetrazolium (NBT) test was the
classic test, but now oxidation of dihydrorhodamine to
rhodamine, analyzed by flow cytometry, is the preferred
method to quantitatively assess the NADPH oxidase
activity of phagocytes. In this test, the intensity of
rhodamine per cell is measured, as well as the fraction of
positive and negative cells. This last property allows
detection of the carrier status in instances of X-linked
CGD, because carriers of X-linked diseases possess a
mosaic of normal and deficient cells due to the random
inactivation of one X chromosome in female cells. Fur-
ther confirmation and characterization of the defect at
the molecular level can be obtained by DNA analysis
and direct sequencing of the relevant gene (11,12).
About two-thirds of the cases of CGD are caused by
defects in gp91
 
phox
 
 encoded by the 
 
CYBB
 
 gene located
on the X chromosome (Xp21.1), and since the expres-
sion of this form is recessive, the disease as a whole is
more common in males. The genes for the other subunits
of the enzyme are located on autosomal chromosomes,
and therefore the remaining cases, comprising predomi-
nantly defects in p47
 
phox
 
, are inherited as autosomal
recessive traits (6,7,9,11). In X-linked CGD (XL-CGD),
several types of mutations have been identified, the most
common being a frame shift due to an insertion of an
adenosine after position 754, where six consecutive ade-
nosines may predispose to recombination errors (9). In
our patient, the mutation in the X-CGD gene 
 
CYBB
 
 was
a frame shift due to an insertion of guanine after G-6,
leading to a stop codon in codon 8.
Cell-mediated immunity in CGD is usually not
affected, even though the macrophages and granulocytes
of these patients have a reduced bactericidal capacity
(13). As described in this case report, there were appro-
priate responses to MMR, DPT, and polio vaccinations,
indicating that cellular immunity was preserved.
Resistance to 
 
Mycobacterium tuberculosis
 
 is
achieved through the cooperation between helper T lym-
phocytes and macrophages (delayed hypersensitivity
type of cellular immunity): stimulation, such as that pro-
duced by mycobacterial infection, causes macrophages
to secrete tumor necrosis factor (TNF)-
 
α
 
, interleukin
(IL)-12, and other factors that promote differentiation
and activation of CD4 Th1 cells to secrete interferon
(IFN)-
 
γ
 
 and other macrophage-activating factors.
Macrophages, in response, secrete TNF-
 
α
 
 and activate
mycobactericidal mechanisms such as nitric oxide pro-
duction (4).
The pathogenesis of disseminated or protracted local
tuberculous infection still remains to be clarified and 
 
M.
tuberculosis
 
 has not been described as a major pathogen
in patients with CGD (9,14). However, taking into
account that the BCG organisms are catalase positive
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and are not killed by CGD phagocytes, it is possible that
even in the apparent absence of impairment of the cellu-
lar immunity, the macrophage defect alone may predis-
pose patients with CGD to develop BCG infections (13).
Defense mechanisms of the phagocytic cells against 
 
M.
tuberculosis
 
 are still unclear, but our findings suggest
that the respiratory burst can play a role (7,14).
The diagnosis of BCG infection can only be con-
firmed by identifying the bacilli through appropriate
staining, culture, or DNA detection. The histopathologic
similarity of granulomas that occur in CGD and BCG
renders the diagnosis of the tuberculous etiology difficult
in patients with CGD. However, inability to identify the
bacilli through culture doesn’t exclude tuberculous etiol-
ogy, and antibacterial treatment is recommended (8,13).
Thus, following this recommendation, our patient was
successfully treated with isoniazid and rifampin.
Although the evidence obtained was suggestive, it
does not allow us to conclude that the adverse reaction
to the BCG vaccination in our patient was a consequence
of his CGD. However, like other authors, we believe that
an unhealed immunization site or the development of
regional lymphadenopathy after a BCG vaccination should
raise the suspicion of CGD (13). Accordingly, a child
who has been diagnosed with CGD or is suspected of
having CGD should not be subjected to BCG vaccina-
tion (13).
The treatment strategy for CGD consists of aggress-
ive treatment of established infections with antibiotics,
and surgical drainage and/or resection of the infec-
tious focus, followed by prophylactic treatment with
trimethoprim-sulfamethoxazole or dicloxacillin for infec-
tions. Itraconazole can be used for antifungal prophylaxis
(11,12). Although not universally used, the prophylactic
administration of recombinant IFN-
 
γ
 
 seems beneficial
(9,11,12).
In spite of a retrospective study conducted in 1989
showing a survival rate of 50% at 10 years of age, the
actual prognosis is better now, and most patients survive
well into adulthood (12). CGD, being a well-characterized
inherited disease, is an ideal candidate to be among the
first diseases to benefit from advances in gene therapy
(9,11,12,15).
Usually there is no increased susceptibility to infec-
tion in female carriers of X-linked CGD, since they have
enough phagocytes with functional NADPH oxidase to
produce an effective host defense (6,9,11). However,
they are predisposed to the development of recurrent
stomatitis, erythematous macular, papular, and urticarial
skin lesions following light exposure and discoid lupus
erythematous (DLE) (6,9,11,16). Nevertheless, some
authors suggest a tenuous link between CGD and DLE
(16), even though in the majority of cases there were
unspecific erythematous rashes, predominantly on photo-
exposed areas, usually described as “lupus-like,” as
was the case in our patient’s mother. This woman had
been followed at the dermatology department over a
number of years without any definitive diagnosis until
her son’s CGD was discovered. Some authors believe
that this dermatosis occurring in X-linked CGD carriers
should have its own identity, even though it shares char-
acteristics with other conditions, namely DLE (16).
Prenatal diagnosis of CGD can be made by analysis
of DNA from cells of the amniotic fluid or chorionic
villi sampling obtained during the 10th
 
−
 
12th week of
gestation. This strategy is dependent on identification of
specific family mutations or on informative polymor-
phisms. Alternatively, measuring the activity of NADPH
oxidase in fetal blood samples during the second trimester
can give the diagnosis (9,11,12).
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